Wall Street brokerages expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to announce earnings of ($0.76) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Redhill Biopharma’s earnings. The highest EPS estimate is ($0.71) and the lowest is ($0.80). Redhill Biopharma posted earnings per share of ($0.70) during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.6%. The firm is expected to issue its next earnings report on Monday, November 13th.

On average, analysts expect that Redhill Biopharma will report full year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.70) to ($2.58). For the next financial year, analysts anticipate that the firm will report earnings of ($2.28) per share, with EPS estimates ranging from ($2.50) to ($2.05). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by $0.02. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million.

Several equities analysts have recently weighed in on RDHL shares. HC Wainwright set a $33.00 price target on Redhill Biopharma and gave the company a “buy” rating in a report on Thursday, June 15th. FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. Zacks Investment Research raised Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a research report on Tuesday, July 4th. Finally, Roth Capital set a $27.00 price objective on Redhill Biopharma and gave the company a “buy” rating in a research report on Monday, July 31st.

Several institutional investors have recently added to or reduced their stakes in RDHL. Renaissance Technologies LLC boosted its position in shares of Redhill Biopharma by 144.1% during the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 36,600 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Redhill Biopharma during the first quarter valued at $276,000. Family Management Corp purchased a new stake in shares of Redhill Biopharma during the first quarter valued at $163,000. Bank of New York Mellon Corp purchased a new stake in shares of Redhill Biopharma during the first quarter valued at $101,000. Finally, Penserra Capital Management LLC boosted its position in shares of Redhill Biopharma by 75.0% during the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares during the last quarter. 10.99% of the stock is currently owned by institutional investors.

Redhill Biopharma (NASDAQ:RDHL) traded down 1.20% during trading on Friday, reaching $8.25. 32,432 shares of the company’s stock were exchanged. Redhill Biopharma has a 12 month low of $8.16 and a 12 month high of $15.35. The firm has a 50 day moving average of $8.92 and a 200-day moving average of $9.42. The stock’s market cap is $141.59 million.

TRADEMARK VIOLATION WARNING: “-$0.76 Earnings Per Share Expected for Redhill Biopharma Ltd. (RDHL) This Quarter” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/09/0-76-earnings-per-share-expected-for-redhill-biopharma-ltd-rdhl-this-quarter-2.html.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.